Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 8, 2002, Pages 622-626

  Watts, Raymond G ^a   Hilliard, Lee M ^a   Berkow, Roger L ^a  

^a ACC 512 ^*  (United States)

Author keywords

Chemotherapy; Epstein Barr virus infection; Immune suppression; Malignant lymphoma; Posttransplant lymphoproliferative disorder; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT PLANNING; UNITED STATES;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BURKITT LYMPHOMA; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FATAL OUTCOME; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LUNG NEOPLASMS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; POSTOPERATIVE COMPLICATIONS; PREDNISONE; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036842439     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200211000-00005     Document Type: Conference Paper

References (20)

1. Swinnen LJ. Overview of post-transplant B-cell lymphoproliferative disorders. Semin Oncol 1999;26(suppl 14):21-5.
2. Sokal EM, Antunes H, Begun C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus related post transplant lymphoproliferative disorder in pediatric liver transplant patients treated with tacrolimus. Transplantation 1997;64:1438-42.
3. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-25.
4. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:365-72.
5. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998;82:1978-87.
6. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998;92:2294-302.
7. Srivastava T, Zwick DL, Rothberg PG, et al. Post transplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999;13:748-54.
8. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
9. Haas RJ, Schmid I, Schon C, Soballa-Stehr E, Stachel D. Non-Hodgkin's lymphoma after heart-lung transplantation: Response to chemotherapy. Med Pediatr Oncol 1999;32:229-30.
10. Dror Y, Greenberg M, Taylor M, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999;67:990-8.
11. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable --------1remission after aggressive chemotherapy for very late post transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000;18:3622-32.
12. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein Barr virus induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982;306:913-8.
13. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus based immunosuppression. Transplantation 1999;68:1851-4.
14. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001;23:14-8.
15. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment of postcardiac transplant lymphoproliferation. Blood 1995;86:3333-40.
16. Balfour IC, Wall D, Luisiri A, et al. Cyclophosphamide/prednisone for combination immunosuppression and therapy of post-transplant lymphoproliferative disease. J Heart Lung Transplant 1999;18:492-5.
17. Benkerrou M, Jais J-P, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphocyte disorder: Prognostic factors and long term outcome. Blood 1998;92:3137-47.
18. Davis CL, Wood BL, Sabath DE, et al. Interferon alpha-treated posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998;66:1770-9.
19. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein Barr virus specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disorder. Proc Natl Acad Sci USA 2000;96:10391-6.
20. Gross TG. Guest commentary: Treatment of Epstein-Barr virus associated post-transplant lymphoproliferative disorders. J Pediatr Hematol Oncol 2001;23:7-9.